DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms)
4 or more days of cannabis use per week
Treatment seeking
A Body Mass Index (BMI) ≥ 22
You may not be if
Meet DSM-5 criteria for Cluster A or B personality disorders and/or unstable current bipolar disorder, schizophrenia, or psychotic disorder
Comorbid severe DSM-5 Major Depressive Disorder
Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale
Any other mental health condition deemed incompatible by the study team
Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months
Positive urine drug screen for any substance except cannabis
Concurrent addiction-focused psychotherapy in the past 6 months
Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months
A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2
Current unstable medical condition
A lifetime diagnosis of Diabetes
Females who are pregnant/nursing, or individuals in reproductive age who do not consent to using birth control during the study
Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide.
Significant literacy, visual, or hearing problems
Co-enrollment in a clinical drug trial
Clareo Health | Tirzepatide in the Treatment of Cannabis Use Disorder
